Invivyd, Inc. (IVVD) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.67 per share a year ago. These figures are ...

PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 ...

Reports FY24 revenue $25.3M, consensus $25.15M. “We are pleased with the significant PEMGARDA revenue growth of 48% in the fourth quarter, ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA (pemivibart) against LP.8.1 Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitu ...

Invivyd, Inc. has announced new in vitro data showing that its monoclonal antibody PEMGARDA™ (pemivibart) maintains effective neutralizing activity against the prevalent LP.8.1 variant of SARS ...

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart ...

New in vitro neutralization data show continued, consistent neutralizing activity of PEMGARDA™(pemivibart) against LP.8.1Centers for Disease Control reports LP.8.1, XEC and KP.3.1.1 together constitut ...

2; affirms structural biology within Invivyd's unique technology and reflects consistently stable epitope for pemivibart VYD2311 also demonstrates stable epitope and clinically meaningful in vitro ...

WALTHAM, Mass., March 05, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, continued, clinically meaningful in vitro neutralization data for PEMGARDA™ (pemivibart) ...

A Stanford-led team has found two antibodies that can work together to neutralize the virus that causes COVID-19 in all its current known variations in a laboratory environment. More research is ...